Trellis Bioscience

Executive Summary

Trellis Bioscience is a clinical-stage biotechnology company leveraging its proprietary CellSpot™ platform to discover native human monoclonal antibodies targeting serious infectious diseases and cancer. Based in South San Francisco, the company focuses on identifying rare, high-affinity antibodies from human memory B cells. Its lead candidate, TRL1068 (calpurbatug), is a broad-spectrum antibody designed to disrupt bacterial biofilms and is currently in Phase 1 development for prosthetic joint infections (PJI), a condition with high unmet need due to antibiotic resistance and limited treatment options. The platform’s ability to isolate potent antibodies against conserved epitopes positions Trellis to address challenging pathogens and oncology targets. Upcoming catalysts include the completion of Phase 1 dose-escalation data for TRL1068 in PJI, which could provide proof-of-mechanism and support advancement into Phase 2 trials. Additionally, Trellis may disclose preclinical data for new pipeline candidates in oncology or infectious disease, potentially expanding its therapeutic scope. A partnership or licensing deal could accelerate development and validate the CellSpot platform. With a focused strategy and a novel approach to antibody discovery, Trellis represents an early-stage opportunity in the biotech space, though clinical execution and funding remain key risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for TRL1068 in prosthetic joint infections65% success
• H1 2027Preclinical data and IND filing for next pipeline candidate40% success
• Q2 2026Strategic partnership or financing deal50% success